Gupta Srishti 4

What Happened

• Srishti Gupta, CEO of NovaBridge Biosciences (NBP), received a grant of 3,000,000 derivative awards (reported as “A” — award/grant) on July 6, 2026. The reported acquisition price is $0.00, meaning no cash was paid at grant. The award is recorded in terms of ADS (American Depositary Shares).

Key Details

• Transaction date: July 6, 2026; Form 4 filed July 8, 2026 (timely within the usual 2-business-day window).
• Amount granted: 3,000,000 ADS-equivalent derivative securities; reported value $0.00 at grant.
• Vesting: Vests and becomes exercisable in four equal annual installments beginning on the first anniversary of July 1, 2026 (i.e., starting July 1, 2027). (Footnote F2)
• ADS/ordinary share conversion: The filing notes ADS representation — each 10 ADSs represent 23 Ordinary Shares. Using that ratio, 3,000,000 ADSs correspond to 6,900,000 Ordinary Shares (Footnote F3).
• Reporting specifics: Number of shares and exercise price are expressed in ADS terms (F1). The filing does not indicate immediate sale or cashless exercise, nor does the provided excerpt state total shares owned after the grant.

Context

• This was a compensation award to the CEO (not an open-market purchase or sale). Such grants are common as part of executive pay and vest over time; they do not necessarily reflect immediate trading sentiment.
• Because the award vests over several years, the economic benefit to the CEO depends on future vesting and any exercise terms; there was no immediate disposition reported.